Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis
Magdalena B. Flak, Romain A. Colas, Estefanía Muñoz-Atienza, Michael A. Curtis, Jesmond Dalli, Costantino Pitzalis
Magdalena B. Flak, Romain A. Colas, Estefanía Muñoz-Atienza, Michael A. Curtis, Jesmond Dalli, Costantino Pitzalis
View: Text | PDF | Corrigendum
Research Article Immunology Inflammation

Inflammatory arthritis disrupts gut resolution mechanisms, promoting barrier breakdown by Porphyromonas gingivalis

  • Text
  • PDF
Abstract

Rheumatoid arthritis is linked with altered host immune responses and severe joint destruction. Recent evidence suggests that loss of gut homeostasis and barrier breach by pathobionts, including Porphyromonas gingivalis, may influence disease severity. The mechanism(s) leading to altered gut homeostasis and barrier breakdown in inflammatory arthritis are poorly understood. In the present study, we found a significant reduction in intestinal concentrations of several proresolving mediators during inflammatory arthritis, including downregulation of the gut-protective mediator resolvin D5n-3 DPA (RvD5n-3 DPA). This was linked with increased metabolism of RvD5n-3 DPA to its inactive 17-oxo metabolite. We also found downregulation of IL-10 expression in the gut of arthritic mice that was coupled with a reduction in IL-10 and IL-10 receptor (IL-10R) in lamina propria macrophages. These changes were linked with a decrease in the number of mucus-producing goblet cells and tight junction molecule expression in the intestinal epithelium of arthritic mice when compared with naive mice. P. gingivalis inoculation further downregulated intestinal RvD5n-3 DPA and Il-10 levels and the expression of gut tight junction proteins. RvD5n-3 DPA, but not its metabolite 17-oxo-RvD5n-3 DPA, increased the expression of both IL-10 and IL-10R in macrophages via the upregulation of the aryl hydrocarbon receptor agonist l-kynurenine. Administration of RvD5n-3 DPA to arthritic P. gingivalis–inoculated mice increased intestinal Il-10 expression, restored gut barrier function, and reduced joint inflammation. Together, these findings uncover mechanisms in the pathogenesis of rheumatoid arthritis, where disruption of the gut RvD5n-3 DPA–IL-10 axis weakens the gut barrier, which becomes permissive to the pathogenic actions of the pathobiont P. gingivalis.

Authors

Magdalena B. Flak, Romain A. Colas, Estefanía Muñoz-Atienza, Michael A. Curtis, Jesmond Dalli, Costantino Pitzalis

×

Figure 6

RvD5n-3 DPA upregulates gut Il-10 expression and restores altered gut barrier function, reducing joint inflammation in P. gingivalis–inoculated arthritic mice.

Options: View larger image (or click on image) Download as PowerPoint
RvD5n-3 DPA upregulates gut Il-10 expression and restores altered gut ba...
Mice were injected with K/BxN serum (50 μL per mouse, i.p.; days 0 and 2) and inoculated with P. gingivalis (109 CFU per mouse) or given vehicle (PBS) on days –1, 1, and 3. In addition, mice were injected i.p. on days 3 and 5 with 200 ng per mouse of RvD5n-3 DPA (K/BxN + P. gingivalis + RvD5n-3 DPA) or vehicle (saline plus 0.1% ethanol; K/BxN + P. gingivalis). Tissues were harvested on day 8. (A) 16S rRNA gene levels were measured by 16S qPCR in mesenteric lymph nodes (MLNs) to assess bacterial translocation across the gut barrier. Results are mean ± SEM and representative of n = 4 mice per group from 2 independent experiments; ***P ≤ 0.001 using Kruskall-Wallis test followed by Dunn’s post hoc test. (B) Representative images of 16S FISH using an Alexa Fluor 488–labeled 16S rRNA gene probe (green) to visualize bacteria and DAPI (blue) to visualize host cells in colons of arthritic vehicle-gavaged control mice and P. gingivalis–inoculated mice injected with vehicle or RvD5n-3 DPA. Dotted lines outline mucus layer; arrows denote bacterial invasion into the gut epithelium (scale bars: 25 μm). Results are representative of n = 4 mice per group from 2 independent experiments. Gene expression of (C) cytokines Tgfb, Il6, Il10, and Il17a , (D) the tight junction protein Tjp1, and the antimicrobial Lyz1 was assessed in ileal mucosal tissue from arthritic mice gavaged with vehicle, inoculated with P. gingivalis, and injected i.p. with RvD5n-3 DPA or controls. Results for C and D are mean ± SEM for n = 3–4 mice per group from 2 independent experiments; Kruskall-Wallis followed by Dunn’s post hoc test; *P ≤ 0.05, **P ≤ 0.01. (E) Immunofluorescence analysis of E-cadherin in small intestines from arthritic mice; scale bars: 25 μm. Results are representative of n = 4 mice per group from 2 independent experiments. (F) Ilea were harvested on day 8, and lipid mediators were identified and quantified using lipid mediator profiling in 7–8 mice per group from 2 independent experiments. (G and H) Mice were inoculated, challenged, and treated as above. (G) Clinical arthritis scores were recorded over time. Results are mean ± SEM for n = 4 mice/time point/group from 2 independent experiments; 2-way ANOVA followed by Bonferroni’s post hoc test; *P ≤ 0.05, K/BxN-injected, P. gingivalis–inoculated, vehicle-injected group (K/BxN + P. gingivalis) versus K/BxN-injected, vehicle-gavaged, vehicle-injected control group (K/BxN); #P ≤ 0.05, ##P ≤ 0.01, K/BxN-injected, P. gingivalis–inoculated, RvD5n-3 DPA–injected group (K/BxN + P. gingivalis + RvD5n-3 DPA) versus K/BxN + P. gingivalis. (H) Swelling indices of edema formation on day 8 in paws and ankles of 8 mice per group from 2 independent experiments; *P ≤0.05 using Kruskall-Wallis followed by Dunn’s post hoc test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts